[Value of Synercid in clinical practice: from temporary approval to clinical trial authorization].

Abstract

NOSOCOMIAL PNEUMONIA DUE TO GRAM-POSITIVE COCCI: In a randomized multicentric trial comparing Synercid with vancomycin, the cure rate (56.3% vs 58.3%) were equivalent in the 2 treatment arms. Treatment failures were also similar: 44% vs 42%. Mortality (25% vs 22%) was likewise comparable, as was tolerance. SKIN AND SOFT TISSUE INFECTIONS: For erysipela, infections requiring surgical dissection, post-trauma infections, postoperative wound infections, or diabetes-related infections, the rate of success obtained in 2 open randomized comparative multicentric trials was equivalent in the 2 treatment arms: 68.2% for Syncercid, 70.7% for the compared treatments. EMERGENCY PRESCRIPTION: For E. faecium, the success rate was 74% based on clinical assessment and 70.5% based on bacteriological assessment. For meti-S S. aureus infections, the clinical success rate was 74% for all patients and 80% for bacteriologically evaluable patients; the bacteriological success rate was 74% and 71% respectively. In case of infection due to C-MLSB meti-R S. aureus, the percentage of clinical success was 89% for bacteriologically evaluable patients.

• Authors: G Potel
• Journal: Presse medicale (Paris, France : 1983) (Presse Med) Vol. 30 Issue 25 Pt 2 Pg. XIX-XXII (Sep 08 2001) ISSN: 0755-4982 [Print] France
• Vernacular Title: Intérêt de Synercid en pratique clinique: de l'ATU à l'AMM.
• PMID: 11603275 (Publication Type: English Abstract, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Virginiamycin
• quinupristin-dalfopristin

Topics

• Anti-Bacterial Agents (adverse effects, therapeutic use)
• Cross Infection (drug therapy)
• Drug Approval (legislation & jurisprudence)
• Drug Resistance, Multiple
• Drug Therapy, Combination (adverse effects, therapeutic use)
• Gram-Positive Bacterial Infections (drug therapy)
• Gram-Positive Cocci (drug effects)
• Humans
• Multicenter Studies as Topic
• Pneumonia (drug therapy)
• Randomized Controlled Trials as Topic
• Soft Tissue Infections (drug therapy)
• Virginiamycin (adverse effects, therapeutic use)